Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75
POLYVIH
Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.
1 other identifier
interventional
136
1 country
1
Brief Summary
Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 19, 2026
CompletedFirst Posted
Study publicly available on registry
February 5, 2026
CompletedStudy Start
First participant enrolled
February 15, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
February 5, 2026
January 1, 2026
1.3 years
January 19, 2026
January 30, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Describe polypharmacy among people living with HIV aged 75 and older.
The average number of medications taken
15 months
Secondary Outcomes (3)
Assess the most common comorbidities associated with polypharmacy in the population of PLHIV aged 75
15 months
Assess whether people taking multiple medications have a lower treatment adherence score than those taking fewer medications.
15 months
Assess the level of functional independence in this age group and link it to the existence of polypharmacy.
15 months
Study Arms (1)
people living with HIV over the age of 75
OTHERInterventions
45 to 60 minutes of interview
Eligibility Criteria
You may qualify if:
- HIV-positive
- Aged 75 or over
- Affiliated with the social security system
- Having expressed no objection to participating in the study
You may not qualify if:
- Refusal to participate
- Known severe cognitive impairment preventing the interview from being conducted
- Patient under guardianship or conservatorship
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de NICE
Nice, CHU de Nice, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2026
First Posted
February 5, 2026
Study Start
February 15, 2026
Primary Completion (Estimated)
May 31, 2027
Study Completion (Estimated)
May 31, 2027
Last Updated
February 5, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share